Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15558418 | 0.83 | — | — | |
| SCHEMBL15558435 | 0.82 | CTH (0.32) | CTH | |
| SCHEMBL15549896 | 0.82 | CTH (0.39) | CTH | |
| SCHEMBL15617036 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL15559019 | 0.81 | CTH (0.31) | CTH | |
| SCHEMBL15559087 | 0.79 | CTH (0.51) | CTH | |
| SCHEMBL15617035 | 0.79 | CTH (0.51) | CTH | |
| SCHEMBL15617012 | 0.79 | CTH (0.51) | CTH | |
| SCHEMBL15617042 | 0.77 | CTH (0.41) | CTH | |
| SCHEMBL15617014 | 0.74 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240276957-A1 | METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS | AGIOS PHARMACEUTICALS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-114174288-A | Methods of treatment with aminolevulinic acid synthase 2(ALAS2) modulators | 安吉奥斯医药品有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2020247819-A2 | METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247819-A2 | METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9725426-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725426-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150266837-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266837-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2015-09-24 | — | — | US | disclosed |
| WO-2015112902-A2 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | SOVA PHARMACEUTICALS, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20150202186-A1 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | SOVA PHARMACEUTICALS, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150202186-A1 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | SOVA PHARMACEUTICALS, INC. | 2015-07-23 | — | — | US | disclosed |
| WO-2014018570-A1 | CYSTATHIONINE-Υ-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327478-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | CTH 2/4885 |
| US-20150266837-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | CTH 2/4885 |
| US-20150202186-A1 | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | CBS, CTH, MTR | CTH 2/4885 |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | HIF1AN, CBS, COXFA4L2 | CTH 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.